QTRX Stock - Quanterix Corporation
Unlock GoAI Insights for QTRX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $135.44M | $121.14M | $105.52M | $110.56M | $86.38M |
| Gross Profit | $81.12M | $73.00M | $45.36M | $64.77M | $48.18M |
| Gross Margin | 59.9% | 60.3% | 43.0% | 58.6% | 55.8% |
| Operating Income | $-52,616,000 | $-45,991,000 | $-104,264,000 | $-56,521,000 | $-31,584,000 |
| Net Income | $-38,531,000 | $-28,354,000 | $-99,574,000 | $-55,548,000 | $-31,530,000 |
| Net Margin | -28.4% | -23.4% | -94.4% | -50.2% | -36.5% |
| EPS | $-1.00 | $-0.86 | $-2.61 | $-1.60 | $-1.07 |
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. The company also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 11th 2025 | Canaccord Genuity | Downgrade | Hold | $5 |
| February 1st 2024 | Scotiabank | Initiation | Sector Outperform | $30 |
| September 25th 2023 | Canaccord Genuity | Upgrade | Buy | $32← $25 |
| August 8th 2023 | SVB Securities | Upgrade | Outperform | $30 |
| May 23rd 2023 | Goldman | Upgrade | Buy | $27← $13 |
| August 15th 2022 | Canaccord Genuity | Downgrade | Hold | $12← $40 |
| August 9th 2022 | Cowen | Downgrade | Market Perform | $18← $38 |
| August 9th 2022 | SVB Leerink | Downgrade | Market Perform | $15← $35 |
Earnings History & Surprises
QTRXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 16, 2026 | $-0.27 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.23 | $-0.36 | -56.5% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.41 | $-0.47 | -14.6% | ✗ MISS |
Q2 2025 | May 12, 2025 | $-0.69 | $-0.53 | +23.2% | ✓ BEAT |
Q1 2025 | Mar 17, 2025 | $-0.27 | $-0.30 | -11.1% | ✗ MISS |
Q4 2024 | Dec 23, 2024 | $-0.24 | $-0.22 | +8.3% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.27 | $-0.25 | +7.4% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $-0.31 | $-0.26 | +16.1% | ✓ BEAT |
Q1 2024 | Feb 29, 2024 | $-0.32 | $-0.33 | -3.1% | ✗ MISS |
Q4 2023 | Nov 6, 2023 | $-0.37 | $-0.21 | +43.2% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | $-0.38 | $-0.16 | +57.9% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.38 | $-0.16 | +57.9% | ✓ BEAT |
Q1 2023 | Mar 6, 2023 | $-0.47 | $-0.50 | -6.4% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-0.42 | $-0.40 | +4.8% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-0.48 | $-0.67 | -39.6% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-0.61 | $-0.49 | +19.7% | ✓ BEAT |
Q1 2022 | Mar 1, 2022 | $-0.66 | $-0.55 | +16.7% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $-0.36 | $-0.43 | -19.4% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-0.33 | $-0.33 | 0.0% | = MET |
Q2 2021 | May 5, 2021 | $-0.33 | $-0.29 | +12.1% | ✓ BEAT |
Latest News
Quanterix Appoints William Donnelly As Executive Chair Of The Board
➖ NeutralQuanterix Publishes A Landmark Study In The Journal Brain; Study Demonstrates Dual GFAP/NfL Blood Test Approach for Personalized Multiple Sclerosis Monitoring
📈 PositiveCORRECTION: Quanterix Q3 Adj. EPS $(0.35) Beats $(0.53) Estimate, Sales $40.233M Beat $37.845M Estimate
📈 PositiveQuanterix Affirms FY2025 Sales Guidance of $130.000M-$135.000M vs $133.465M Est
➖ NeutralQuanterix Q3 EPS $(0.73) Misses $(0.38) Estimate, Sales $40.233M Beat $37.845M Estimate
➖ NeutralQuanterix From4 Filing Shows CFO Vandana Sriram Bought 4,150 Shares At An Average Price Of $4.79/Share
📈 PositiveQuanterix Accelerator Laboratory Receives New York State Clinical Laboratory Permit; Permit Approval Enables Expanded Research Capabilities And Underscores Commitment To Accuracy, Reliability, And Scientific Excellence
📈 PositiveAkoya surges as unsolicited buyout offer risks Quanterix merger
📈 PositiveFrequently Asked Questions about QTRX
What is QTRX's current stock price?
What is the analyst price target for QTRX?
What sector is Quanterix Corporation in?
What is QTRX's market cap?
Does QTRX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to QTRX for comparison